Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study (vol 97, pg 1, 2018)

Alexander Egle,Michael Steurer,Thomas Melchardt,Lukas Weiss,Franz Josef Gassner,Nadja Zaborsky,Roland Geisberger,Kemal Catakovic,Tanja Nicole Hartmann,Lisa Pleyer,Daniela Voskova,Josef Thaler,Alois Lang,Michael Girschikofsky,Andreas Petzer,Richard Greil

ANNALS OF HEMATOLOGY（2018）

引用 1|浏览5

暂无评分

摘要

The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann. The original article has been corrected.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要